Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension

OBJECTIVES: To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period. METHODS: Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offere...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Joakim, Burman, Joachim, Bergenheim, Tommy, Svenningsson, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880973/
https://www.ncbi.nlm.nih.gov/pubmed/32901316
http://dx.doi.org/10.1007/s00415-020-10210-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880973/
https://www.ncbi.nlm.nih.gov/pubmed/32901316
http://dx.doi.org/10.1007/s00415-020-10210-0

Ejemplares similares